언어 선택

HGF

HGF 분자 정보

영어 이름	Hepatocyte growth factor	시판 약물 수	1
임상 약물 수	7	표적 별명	EC 3.4.21.7，Hepatocyte Growth Factor (Hepapoietin A; Scatter Factor)，EC 3.4.21，HGF，Hepatopoietin-A，Scatter factor，Hepatocyte Growth Factor (Hepapoietin A，Scatter Factor)，Fibroblast-Derived Tumor Cytotoxic Factor，Lung Fibroblast-Derived Mitogen，SF，Deafness， Autosomal Recessive 39，Hepatopoietin A，DFNB39，F-TCF，HGFB，Hepatocyte Growth Factor，HPTA
최고 연구 개발 단계	Approved

영어 이름	Hepatocyte growth factor
표적 별명	EC 3.4.21.7，Hepatocyte Growth Factor (Hepapoietin A; Scatter Factor)，EC 3.4.21，HGF，Hepatopoietin-A，Scatter factor，Hepatocyte Growth Factor (Hepapoietin A，Scatter Factor)，Fibroblast-Derived Tumor Cytotoxic Factor，Lung Fibroblast-Derived Mitogen，SF，Deafness， Autosomal Recessive 39，Hepatopoietin A，DFNB39，F-TCF，HGFB，Hepatocyte Growth Factor，HPTA
시판 약물 수	1
임상 약물 수	7
최고 연구 개발 단계	Approved

HGF 제품 목록

속성
Protein (4)Kits (1)
제품 라이브러리
온라인 (5)
종
Human (5)
태그
His Tag (1)Fc Tag (1)- (1)Tag Free (2)
마커
Unconjugated (4)- (1)

제품 번호	종	발현 시스템	제품 설명
HOT HGF-H5218	Human	HEK293	Human HGF Protein, premium grade
HOT HGF-H5253	Human	HEK293	Human HGF Protein, Fc Tag (MALS verified)
HOT HGF-H52H3	Human	HEK293	Human HGF Protein, His Tag, low endotoxin (MALS verified)
CRS-B012	Human	-	Human HGF ELISA Kit
GMP-HGFH28	Human	HEK293	GMP Human HGF Protein

총 수량5

HGF분자 배경

Hepatocyte growth factor (HGF) is a paracrine cellular growth, motility and morphogenic factor. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization. Hepatocyte growth factor is secreted by mesenchymal cells and acts as a multi-functional cytokine on cells of mainly epithelial origin. Its ability to stimulate mitogenesis, cell motility, and matrix invasion gives it a central role in angiogenesis, tumorogenesis, and tissue regeneration. In addition, HGF has been implicated in a variety of cancers, including of the lungs, pancreas, thyroid, colon, and breast.

HGF분자 별명

HGF,HPTA,SF

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Fosgonimeton	NDX-1017; ATH-1017; ATH 1017	Phase 3 Clinical	M3 Biotechnology	Alzheimer Disease; Dementia; Lewy Body Disease; Parkinson Disease	상세
RGL-2102	RGL-2102; RGL2102	Phase 3 Clinical	Shanghai Regenelead Therapies Co Ltd	Diabetic Foot; Ischemia; Ulcer; Wound Infection	상세
Ficlatuzumab	AV-299; SCH-900105	Phase 3 Clinical	Aveo	Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cholangiocarcinoma; Colonic Neoplasms; Glioblastoma; Head and Neck Neoplasms; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Lymphoma; Multiple Myeloma; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Respiratory Tract Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck	상세
Umikibart	YYB-101; NOV-1105; CLM-101	Phase 2 Clinical	YooYoung Pharmaceutical Co Ltd	Colorectal Neoplasms; Solid tumours	상세
ATH-1020	ATH-1020	Phase 1 Clinical	Athira Pharma Inc	Nerve Degeneration	상세
ATH-1105	ATH-1105	Phase 1 Clinical	Athira Pharma Inc	Amyotrophic Lateral Sclerosis; Frontotemporal Dementia	상세
Microbiome-optimized autologous stem cell therapy (Biotech Holdings)		Clinical	Biotech Holdings	Peripheral Vascular Diseases	상세

시판 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	가장 빠른 브랜드 이름	가장 빠른 승인 국가	가장 빠른 적응증	가장 빠른 승인 회사	가장 빠른 승인 날짜	적응증	임상 시험
Beperminogene perplasmid	AMG-0001-01; AMG-0001; DS-992; TREAT-HGF	Approved	Anges Mg, Osaka University	Collategene	Japan	Peripheral Arterial Disease; Ischemia	Anges Inc, null	2019-03-01	Arterial Occlusive Diseases; Atherosclerosis; Foot Ulcer; Ischemia; Peripheral Arterial Disease; Peripheral Vascular Diseases; Ulcer; Vascular Diseases	상세